Argenica Therapeutics
- Short interest
- 0.01%
- +0.01 pp 30d
- as of 3 July 2026
- Reported shorts
- 15.2K
- Shares on issue
- 128.457M
Argenica Therapeutics (AGN) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $212.0KM (source: ASX (Markit))vs $512.8KM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$1.4MM (source: ASX (Markit))vs −$7.2M (FY25)
- ASX (Markit), as at 14 Oct 2026
- EPS (diluted)
- −$0.011T (source: Derived: trailing 12 months at year end)vs −$0.056 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- −58.7%FY
- EPS YoY
- n/aTTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Summary of Appendix 4E & Annual Report to 30 June 2026, 26 Aug 2026
Argenica Therapeutics' full-year loss narrowed 81% to $1.37 million, while revenue jumped 53% to $5.70 million, driven by R&D tax incentives and government grants. No dividend was declared. The company is advancing its lead drug candidate xaranetide toward a late-stage stroke trial, having successfully completed Phase 2 safety and efficacy studies.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- −3,330.6%
- Net margin
- −644.0%
- FCF margin
- −1,976.1%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- −22,561.1×
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: ASX (Markit) and Derived: trailing 12 months at year end, as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $212.0KM (source: ASX (Markit)) | $512.8KM (source: ASX (Markit)) | $192.1KM (source: ASX (Markit)) | $61.0KM (source: ASX (Markit)) |
| Operating income | −$7.1MT (source: Derived: trailing 12 months at year end) | −$10.9M | −$8.3M | −$6.6M |
| EBITDA | −$1.4MT (source: Derived: trailing 12 months at year end) | −$7.2M | −$5.5M | −$4.8M |
| EBIT | −$1.4MT (source: Derived: trailing 12 months at year end) | −$7.2M | −$5.5M | −$4.8M |
| Interest expense | $313T (source: Derived: trailing 12 months at year end) | $503 | $369 | $1.1K |
| Pretax income | −$1.4MT (source: Derived: trailing 12 months at year end) | −$7.2M | −$5.5M | −$4.8M |
| Tax | $0T (source: Derived: trailing 12 months at year end) | $0 | $0 | $0 |
| NPAT | −$1.4MM (source: ASX (Markit)) | −$7.2M | −$5.5M | −$4.8M |
| Net interest income | $211.7KT (source: Derived: trailing 12 months at year end) | $512.2K | $191.7K | $59.9K |
| EPS basic | −$0.011T (source: Derived: trailing 12 months at year end) | −$0.056 | −$0.053 | −$0.055 |
| EPS diluted | −$0.011T (source: Derived: trailing 12 months at year end) | −$0.056 | −$0.053 | −$0.055 |
| Shares | n/a | 128.4M | 123.7M | 98.4M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Appendix 4E & Annual Report to 30 June 2026Annual Results26 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report24 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Apr 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results11 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Oct 2025via asx_announcements
- Appendix 4E & Annual Report to 30 June 2025Annual Results28 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report23 Jul 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2025via asx_announcements
- Half Yearly Report and AccountsHalf Year Results11 Feb 2025via asx_announcements
Showing 10 of 50 reports